1.Comparison of the results of plasma scalpel assisted UPPP with radiofrequency volumetric tissue reduction in the treatment of obstructive sleep apnea hypopnea syndrome
Zhihong LUO ; Zhidan MEI ; Shiming CHEN ; Zezhang TAO ; Yongmao CAO
Chinese Archives of Otolaryngology-Head and Neck Surgery 2006;0(06):-
OBJECTIVE To compare the results of plasma scalpel assisted uvulopalatopharyngoplasty(UP PP) under local anesthesia(PS)with radiofrequency volumetric tissue reduction(RF)in the treatment of obstructive sleep apnea/hypopnea syndrome (OSAHS). METHODS Sixty-nine and 79 patients were treated with PS and RF respectively. They were followed-up for 6 and 12 months after operation and the outcomes of the 2 surgical methods were compared. RESULTS The improvement rates at 6 months after PS and RF were 85.5 % and 83.5 % respectively. There was no significant difference between the 2 methods. The improvement rates at 12 months after PS and RF were 78.3 % and 49.3 % respectively. The difference was significant. No major complication was found. CONCLUSION The long-term outcome of PS is better than that of RF. PS surgery may be comparable with surgery under general anesthesia in some special cases.
2.Effect of Personality Characteristics on Near-term Postoperative Mental Health of Male Patients with Laryngeal Squamous Cell Carcinoma
Ning AN ; Daqing FAN ; Fangqin YU ; Zhidan MEI
Cancer Research on Prevention and Treatment 2022;49(7):682-686
Objective To investigate the effect of personality characteristics on near-term postoperative mental health of patients with laryngeal squamous cell carcinoma (LSCC). Methods We included 119 patients with LSCC who underwent surgical treatment. The recent psychological state was assessed by SCL-90, SAS and SDS 5 to 7 days after surgery. The EPQ was used to evaluate the personality characteristics of patients after operation. Multiple linear stepwise regression method was used to analyze the influencing factors of SAS and SDS scores of LSCC patients. Results The postoperative scores of SCL-90, SAS and SDS of LSCC patients were significantly higher than the Chinese norm (
3.Efficacy and safety of vonoprazan in the treatment of gastroesophageal reflux disease:a meta-analysis
Jiaxi TANG ; Mengran GUO ; Tianfei FAN ; Zhidan WANG ; Mei ZHAN ; Minglin ZHENG ; Ping FAN
China Pharmacy 2023;34(6):735-739
OBJECTIVE To systematically evaluate the efficacy and safety of vonoprazan in the treatment of gastroesophageal reflux disease, and to provide evidence-based reference for clinical drug use. METHODS Randomized controlled trials (RCTs) about vonoprazan (trial group) versus placebo or proton pump inhibitor (control group) were searched in PubMed, the Cochrane Library, Web of Science, CNKI, Wanfang, VIP and CBM databases from the inception to June, 2022. After literature screening and data extraction, the qualities of included literature were evaluated with bias assessment tool recommended by Cochrane system evaluator manual 5.1.0. Meta-analysis, sensitivity analysis and publication bias analysis were conducted by using RevMan 5.4 software. RESULTS A total of 9 RCTs were included, involving 1 882 patients. The results of meta-analysis showed that: total response rate [OR=1.94,95%CI(1.45,2.58),P<0.000 01], cure rate [OR=2.27,95%CI(1.33,3.86),P=0.003] and remission rate [OR=1.81,95%CI(1.28, 2.55), P=0.000 7] of trial group were significantly higher than control group; there was no significant difference in the incidence of adverse drug events, diarrhea, nasopharyngitis, upper respiratory tract infection and alkaline phosphatase elevation between two groups (P>0.05). The results of subgroup analysis showed that cure rate of trial group was significantly higher than control group at 2 weeks of treatment (P<0.05); at 4 and 8 weeks of treatment, there was no significant difference in the cure rate between two groups (P>0.05). There was no statistically significant difference in the cure rate between two groups at 2, 4 and 8 weeks of treatment among the patients with Los Angeles grade A/B (P>0.05); among the patients with Los Angeles grade C/D, the cure rate of patients in the trial group was significantly higher than control group at 2, 4 and 8 weeks of treatment (P<0.05). The results of sensitivity analysis and publication bias analysis showed that the results of this study were robust and the possibility of publication bias was small. CONCLUSIONS Vonoprazan has a considerable effectiveness and safety in the treatment of gastroesophageal reflux disease.